Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acamprosate + baclofen
- Development stage
- Phase 2
- Lead developer
- Pharnext
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Acamprosate + baclofen** is Pharnext's low-dose, orally administered repurposed-drug combination developed as PXT864 and PXT00864 for mild Alzheimer's disease. Baclofen is a gamma-aminobutyric acid type B receptor agonist, while acamprosate has incompletely resolved pharmacology and is thought to modulate glutamatergic neurotransmission. Pharnext proposed that combining the agents could restore disrupted inhibitory GABAergic and glycinergic versus excitatory glutamatergic signaling associated with amyloid-beta oligomer toxicity. The PLEODIAL-I and PLEODIAL-II studies evaluated the combination in mild Alzheimer's disease; Pharnext stopped its Alzheimer's disease development program in February 2023 for financial and prioritization reasons. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02361424))
- Brand names
- PXT864PXT-864PXT 864
- Other names
- baclofen + acamprosate
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)GRM5 (Metabotropic glutamate receptor 5)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on acamprosate + baclofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acamprosate + baclofen.